Walleye Capital
AGIO icon

Walleye Capital’s Agios Pharmaceuticals AGIO Stock Holding History

Walleye Capital’s Portfolio AGIO Stock Details AGIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-19,200
Closed -$771K – 4507
2025
Q3 		$771K Buy
+19,200
New +$722K ﹤0.01% 2295
2025
Q1 		– Sell
-15,200
Closed -$499K – 4176
2024
Q4 		$499K Sell
15,200
-600
-4% -$28.2K ﹤0.01% 2981
2024
Q3 		$702K Buy
15,800
+700
+5% +$31.8K ﹤0.01% 2985
2024
Q2 		$651K Buy
15,100
+5,800
+62% +$209K ﹤0.01% 3267
2024
Q1 		$272K Buy
9,300
+4,200
+82% +$112K ﹤0.01% 3744
2023
Q4 		$114K Sell
5,100
-6,000
-54% -$134K ﹤0.01% 3996
2023
Q3 		$275K Buy
+11,100
New +$294K ﹤0.01% 3305
2020
Q1 		– Sell
-28,100
Closed -$1.34M – 857
2019
Q4 		$1.34M Sell
28,100
-18,700
-40% -$707K 0.09% 315
2019
Q3 		$1.52M Buy
46,800
+5,500
+13% +$228K 0.09% 303
2019
Q2 		$2.06M Buy
41,300
+29,700
+256% +$1.59M 0.23% 83
2019
Q1 		$782K Buy
+11,600
New +$676K 0.13% 231

Other funds holding AGIO

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $58.4B AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BNP Paribas Asset Management
BNP Paribas Asset Management Paris, France $86.1B AUM 29.11% 1-Year Est. Return

Walleye Capital's AGIO Position: Q2 2025 in Review

Walleye Capital sold out of Agios Pharmaceuticals (AGIO) in Q2 2025, closing a stake of 150,511 shares — an estimated $4.41M sold.

Walleye Capital first reported a position in AGIO in Q1 2019 and held it in 9 quarters. The position peaked at $7.49M in Q4 2023. 214 funds tracked by Wall St. Rank hold AGIO as of Q2 2025.

  • Walleye Capital reported no remaining Agios Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • Walleye Capital sold 150,511 Agios Pharmaceuticals shares in Q2 2025, an estimated $4.41M.
  • Walleye Capital first reported a position in Agios Pharmaceuticals in Q1 2019 and held it in 9 quarters.
  • Walleye Capital's Agios Pharmaceuticals position peaked at $7.49M in Q4 2023.
  • 214 funds tracked by Wall St. Rank held Agios Pharmaceuticals as of Q2 2025.

Based on Walleye Capital's 13F filing for Q2 2025, filed 13 Aug 2025.